On Thursday, Verint Systems Inc. (NASDAQ:VRNT)’s shares declined -4.34% to $63.47.
Verint Systems Inc. (VRNT) declared results for the three months ended April 30, 2015.
Financial Highlights
Below is selected unaudited financial information for the three months ended April 30, 2015 prepared in accordance with generally accepted accounting principles (“GAAP”) and not in accordance with GAAP (“non-GAAP”).
Financial Outlook
For the year ending January 31, 2016, we are maintaining our non-GAAP revenue guidance range of $1.20 billion to $1.25 billion and non-GAAP diluted earnings per share guidance range of $3.55 to $3.75.
Verint Investor Day
As formerly declared, Verint is holding an investor day on June 9, 2015 in Las Vegas. The event will take place from 10:30 a.m. - 5:00 p.m. PT at the Paris Hotel, the same venue as the company’s Engage™ enterprise global customer conference. Verint Investor Day will feature presentations from the company’s administration team, talk about with Verint enterprise customers, and demonstrations of the company’s solutions, counting its next generation cyber threat protection solution.
Verint Systems Inc. provides actionable intelligence solutions and value-added services worldwide. The company operates through three segments: Enterprise Intelligence Solutions, Communications and Cyber Intelligence Solutions, and Video and Situation Intelligence Solutions.
CarMax, Inc (NYSE:KMX)’s shares gained 0.38% to $73.09.
CarMax, Inc. (KMX) declared the webcast and conference call access information for forthcoming events.
On June 19, CarMax, will release sales and earnings for the first quarter ended May 31, 2015, and will host a conference call for investors at 9:00 a.m. ET.
A webcast replay of the call will be accessible at investors.carmax.com through September 21, 2015. A telephone replay also will be accessible through June 26, 2015.
- The CarMax 2015 annual meeting of shareholders will be held on Monday, June 22, at the Hilton Richmond Hotel, Short Pump, in Richmond, Va., starting at 1:00 p.m. ET. A live webcast of the meeting will be accessible at investors.carmax.com. The webcast replay will be accessible through July 22, 2015.
- June 24, 2015 – Oppenheimer’s 15th Annual Consumer Conference
- Katharine W. Kenny, Vice President, Investor Relations, will present at Oppenheimer’s 15th Annual Consumer Conference on June 24, 2015, at the Four Seasons Hotel Boston. The presentation will start at 9:05 a.m. ET. A live webcast of the presentation will be accessible at investors.carmax.com. The webcast replay will be accessible through September 24, 2015.
CarMax, Inc., through its auxiliaries, operates as a retailer of used vehicles in the United States. The company operates in two segments, CarMax Sales Operations and CarMax Auto Finance. It offers customers a range of makes and models of used vehicles, counting domestic and imported vehicles; sells vehicles that do not meet its retail standards to licensed dealers through on-site wholesale auctions; and provides extended protection plans to customers at the time of sale. In addition, the company offers reconditioning and vehicle repair services; and provides financing alternatives for retail customers across a range of credit spectrum through its CarMax Auto Finance and arrangements with other financial institutions. Further, it sells new vehicles under franchise agreements.
At the end of Thursday’s trade, Black Stone Minerals LP (NYSE:BSM)‘s shares dipped -0.22% to $17.81.
Black Stone Minerals LP (BSM) declared its financial and operating results for the first quarter of 2015.
Key First Quarter 2015 Highlights:
- Average daily production of 29.2 MBoe per day
- Revenues of $91.1 million
- Net income of $17.3 million and Adjusted EBITDA (as defined below) of $60.9 million
Thomas L. Carter, Jr., Black Stone Minerals’ President, Chief Executive Officer, and Chairman commented, “Our strong first-quarter production of 29.2 MBoe per day comfortably exceeded our average daily production target of 26.3 MBoe per day that we offered in our prospectus for the twelve months ending March 31, 2016, despite comparatively low commodity prices during the period. We are optimistic that we will meet or exceed our production forecast for the next twelve months.
Financial and Operating Results
Production
Black Stone Minerals stated average daily production of 29.2 MBoe per day for the first quarter of 2015, an enhance of 14.8% over average daily production of 25.4 MBoe per day for the corresponding period in 2014. The enhance in production was primarily attributable to raised drilling activity in the Bakken/Three Forks, Eagle Ford, Haynesville/Bossier, and Wilcox plays.
Black Stone Minerals, L.P., together with its auxiliaries, owns oil and natural gas mineral interests in the United States. The company owns mineral interests in about 14.5 million acres; nonparticipating royalty interests in 1.2 million acres; and overriding royalty interests in 1.4 million acres in the Bakken/Three Forks plays, Eagle Ford Shale, Wolfcamp play, Haynesville/Bossier plays, Granite Wash play, and Fayetteville Shale, in addition to in the Tuscaloosa Marine Shale and the Canyon Lime play located in 41 states and in 62 onshore basins in the continental United States.
Array Biopharma Inc (NASDAQ:ARRY), ended its Thursday’s trading session with -0.97% loss, and closed at $7.64.
Array Biopharma Inc (ARRY) were showcased at the 2015 annual meeting of the American Society of Clinical Oncology (ASCO). At the meeting, preliminary data for the combination of binimetinib and encorafenib from a Phase 1b/2 dose escalation and expansion study in patients with BRAF-mutant melanoma who are BRAF inhibitor treatment naive were shared during an oral presentation. Results from the study indicate that binimetinib and encorafenib may be safely combined and show encouraging clinical activity comprising with MEK/BRAF inhibitor expectations in patients with BRAF-mutant melanoma who are BRAF inhibitor treatment naive. In addition, a differentiated safety profile relative to other MEK/BRAF inhibitor combinations is emerging in the dose range presently being used in the Phase 3 COLUMBUS trial. Array anticipates updated BRAF melanoma data from the ongoing Phase 2 combination trial (LOGIC-2) of binimetinib and encorafenib followed by the addition of a third targeted agent identified based on genetic testing at the time of progression will be presented to a scientific conference later this year. LOGIC-2 utilizes the same dose of binimetinib and encorafenib presently being studied in the COLUMBUS trial.
Preliminary data from the study also indicate that in combination with binimetinib, encorafenib was tolerated at doses up to 600 mg, twice its single-agent maximum tolerated dose. At the 400/450 mg dose of encorafenib, with few grade 3 / 4 events and an 11 percent incidence of pyrexia and photosensitivity, a differentiated safety profile relative to other MEK/BRAF inhibitor combinations is emerging.
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company’s products in Phase III clinical trials comprise Binimetinib and Encorafenib for the treatment of cancer. Its clinical programs in Phase II clinical trial comprise ARRY-797, a p38 program for Lamin A/C-related dilated cardiomyopathy; and ARRY-502, a CRTh2 antagonist to treat Th2-driven allergic disease.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
